Request Trial
img_1651
22 October 2019AmericasSarah Morgan

LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda

While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Moderna: BioNTech is claiming work ‘it never did’
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.
Americas
US biotech fires trade secrets suit at Chinese pharma group
10 June 2026   Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026   A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

More features

Moderna: BioNTech is claiming work ‘it never did’
Siemens ordered to recall mammography device across European countries
MoFo bags IP trial duo with 50 years’ combined experience
US biotech fires trade secrets suit at Chinese pharma group
Hikma v Amarin: Six takeaways from the pivotal ruling
Exclusive: ‘When a UPC judge wears their robe, they have no gender’
Clarivate’s new IP president to ‘usher in next phase of growth’
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm